Phase 3 Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People diagnosed with either a mild ("non-disabling") ischaemic stroke or a transient ischaemic attack (TIA, sometimes called a "mini-stroke") that carries a moderate to high risk of a further stroke, based on specific scoring tools used by doctors
• People whose symptoms started no more than 48 hours before entering the trial
• People whose blood test results, taken 5–20 hours after starting a specific combination of two blood-thinning medications (clopidogrel 300 mg and aspirin 100 mg), show that their platelets (cells that help blood clot) are still highly active at a level of 35% or above on a specific test called MARADP (confirm with trial site)
• People who have given written consent to take part, either themselves or through a legal representative

Who may not be able to join:

• People whose brain scans show a bleeding stroke, bleeding within a previous stroke, or other brain conditions such as abnormal blood vessels, tumours, abscesses, or diseases like multiple sclerosis
• People whose stroke or TIA was caused by a procedure to open or repair blood vessels
• People whose heart tracing (ECG) or physical examination shows signs of an irregular heartbeat condition called atrial fibrillation
• People who have a clear medical need for blood-thinning medications called anticoagulants (for example, because of atrial fibrillation, an artificial heart valve, or a suspected heart-related clot)
• People who have already received, or are planned to receive within 90 days, clot-dissolving treatments or procedures to restore blood flow to the brain (such as thrombolysis or thrombectomy)
• People who have taken blood-thinning medications other than aspirin and clopidogrel (such as ticagrelor or prasugrel) within the past 7 days
• People with a recent history of bleeding in the stomach or intestines, bleeding in the brain, heavy bleeding requiring a blood transfusion, or bleeding disorders that affect how blood clots (such as purpura)
• People who cannot tolerate or have a known reason to avoid clopidogrel, ticagrelor, or aspirin — including known allergies to these medicines, severely reduced liver or kidney function, severe heart failure, clotting disorders, a history of low platelet or white blood cell counts caused by a drug, or a history of liver problems caused by medication
• People with abnormally low white blood cell counts or low platelet counts on blood tests
• People who have used heparin or oral anticoagulant (blood-thinning) medications within the 10 days before entering the trial
• People with severe problems affecting the heart, lungs, liver, or kidneys, or serious conditions such as cancer, severe dementia, or severe breathing problems
• Women of childbearing age who are not willing to use effective contraception during the trial; women who are pregnant or breastfeeding
• People who are unlikely to be able to follow the requirements of the study reliably

Important: Always verify eligibility with the trial site directly before applying.